• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Destruxin B

Destruxin B

Product ID D183745
Cas No. 2503-26-6
Purity ≥96%
Product Unit SizeCostQuantityStock
100 µg $102.30 In stock
1 mg $613.20 In stock
5 mg $2,452.90 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Destruxin B, a cyclic depsipeptide, is a secondary metabolite isolated from the fungus Metarhizium anisopliae. Each of the mycotoxins, destruxin A, B, and E, were individually found to display antitumor effects on leukemic cells in vitro. In addition, each destruxin was found to produce antiproliferative effects in colon cancer cells and to inhibit the migration and tube formation of human endothelial cells. Although the inhibition of vacuolar-type ATPase by destruxin B has been found to be weaker than bafilomycin A1, inhibition by destruxin B was found to be readily reversible, which makes it more useful as a probe of V-ATPase function. In human colorectal cancer cells destruxin B treatment resulted in suppressed proliferation and induced cell cycle arrest. Administration of destruxin B to human non-Hodgkin lumphoma cells resulted in apoptosis induced by attenuation of the mitochondrial membrane potential.

Product Info

Cas No.

2503-26-6

Purity

≥96%

Formula

C30H51N5O7

Formula Wt.

593.77

Chemical Name

Destruxin B

IUPAC Name

16-butan-2-yl-10,11,14-trimethyl-3-(2-methylpropyl)-13-propan-2-yl-4-oxa-1,8,11,14,17-pentazabicyclo[17.3.0]docosane-2,5,9,12,15,18-hexone

Synonym

MLS002702090; AC1L8LE6; MEGxm0_000393

Melting Point

230-240°C

Appearance

White powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

D183745 MSDS PDF

Info Sheet

D183745 Info Sheet PDF

References

Yeh CT, Rao YK, Ye M, et al. Preclinical evaluation of destruxin B as a novel Wnt signaling target suppressing proliferation and metastasis of colorectal cancer using non-invasive bioluminescence imaging. Toxicol Appl Pharmacol. 2012 May 15;261(1):31-41. PMID: 22465936.

Odier F, Vey A, Bureau JP. In vitro effect of fungal cyclodepsipeptides on leukemic cells: study of destruxins A, B, and E. Biol Cell. 1992;74(3):267-271. PMID: 1628110.

Dornetshuber-Fleiss R, Heffeter P, Mohr T, et al. Destruxins: fungal-derived cyclohexadepsipeptides with multifaceted anticancer and antiangiogenic activities. Biochem Pharmacol. 2013 Aug 1;86(3):361-377. PMID: 23747344.

Muroi M, Shiragami N, Takatsuki A. Destruxin B, a specific and readily reversible inhibitor of vacuolar-type H(+)-translocating ATPase. Biochem Biophys Res Commun. 1994 Dec 15;205(2):1358-1365. PMID: 7802670.

Chao PZ, Chin YP, Hsu IU, et al. Apoptotic toxicity of destruxin B in human non-Hodgkin lymphoma cells. Toxicol In Vitro. 2013 Sep;27(6):1870-1876. PMID: 23751424.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • O7377

    Osthole

    O-methylated coumarin; Ca2+ channel blocker.

    ≥98%
  • A0963

    Adrenocorticotropic Hormone (1-10), human

    Endogenous peptide hormone fragment, involved i...

    ≥95%
  • L9704

    LY-2603618

    Chk1 inhibitor.

    ≥98%
  • C0172

    Carbimazole

    Methimazole prodrug; thyroid peroxidase inhibit...

    ≥98%
  • D1761

    15-Acetyl-deoxynivalenol

    Type A trichothecene mycotoxin produced by Fusa...

    ≥98%, TLC
  • C6132

    CPI-203

    Triazolothienodiazepine, JQ-1 derivative; BRD i...

    ≥98%
  • I6933

    Irinotecan Hydrochloride Trihydrate

    Camptothecin analog; topoisomerase I inhibitor,...

    ≥98%
  • G6817

    Green Tea Polyphenols

    Extract containing catechins and flavonoids fou...

    ≥98%
  • F1745

    Felodipine

    Dihydropyridine; L-type Ca2+ channel blocker.

    ≥98%
  • O4578

    Oltipraz

    Antioxidant; Nrf2 activator.

    ≥98%
  • R5774

    Roscovitine

    CDK inhibitor, L-type Ca2+ channel blocker.

    ≥98%
  • P004080

    PAC-1

    Zinc chelator

    ≥98%
  • C1627

    Cefaclor Monohydrate

    β-lactam cephalosporin; penicillin binding pro...

    ≥97%
  • M9608

    Myclobutanil

    14-α demethylase inhibitor.

    ≥97%
  • E9417

    Exendin-4

    Peptide, GLP-1 analog found in Heloderma; GLP-1...

    ≥95%
  • L589940

    LOXO-101

    Inhibitor of tropomyosin kinase receptors TRKA,...

    ≥99%
  • R0154

    Ranolazine Dihydrochloride

    Nav1.7 and Nav1.8 N1+ channel blocker.

    ≥98%
  • D1850

    Demethoxycurcumin

    Curcumin derivative; AMPK activator, STAT3 and ...

    ≥98%
  • E5216

    β-Endorphin, camel

    Endogenous opioid peptide; μOR agonist.

    ≥95%
  • B0025

    Bafilomycin A1

    Macrolide antibiotic; vacuolar H+ ATPase inhibi...

    ≥90%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only